:::::::::: 글로벌번역통역센터 ::::::::::
 
 



 
 
> 고객지원센터 > News & Notice
ADMIN 2020. 11. 30.  
LIST  MODIFY  DELETE  WRITE  REPLY 
   제목: Celltrion fires opening salvo against JPMorgan


Celltrion fires opening salvo against JPMorgan


September 11,2020

By Park Jae-hyuk

Celltrion, Korea's leading pharmaceutical company, hinted at taking legal action against top-tier U.S. investment bank JPMorgan, by claiming the bank's recent investment reports on the firm defamed its chairman Seo Jung-jin and the company.

Celltrion held an emergency briefing for securities firm analysts here, Thursday, after the company officially raised questions about the credibility of the recent JPMorgan investment reports. The Korea Times reached out JPMorgan for any comments on Celltrion's claim, but received no response.

The possibility came after JPMorgan & Chase abruptly accentuated its negative outlook for the Korean pharmaceutical firm.

In the report published by JPMorgan analyst Cho Ji-hyun, Wednesday, the investment bank suggested a reduction of investments in Celltrion shares, setting its target price at 190,000 won ($160), about 60 percent of the previous session's closing price of 318,000 won.

As for Celltrion Healthcare share, JPMorgan set its target price at 70,000 won, about 70 percent of the previous session's closing price of 103,100 won.

JPMorgan said Celltrion's annual earnings growth will peak at 54 percent in 2020 and fall to 21 percent in 2021, warning investors against being too optimistic about its development of potential COVID-19 treatments.

As the stock prices of Celltrion and Celltrion Healthcare respectively dropped 6.13 percent and 4.36 percent after the issuance of the report, the Korean pharmaceutical company claimed JPMorgan seemingly published an "unreasonable report" to undervalue Celltrion, compared to its rival.

In the same report, JPMorgan raised the target price of an ordinary share of Samsung Biologics to 840,000 won from 416,000 won. Samsung Biologics closed at 774,000 won a day before the publication of the report.

"Based on its own estimation of the 2021 earnings, JPMorgan calculated our rival's price to earnings ratio (PER) next year to be 158 times, while Celltrion's to be 76 times and Celltrion Healthcare's 57 times," Celltrion CEO Kee Woo-sung said in a statement. "However, it suggested 'underweight' for Celltrion and Celltrion Healthcare, while proposing 'neutral' for our rival."

Local investors suspected the U.S. investment bank was intentionally trying to drag down its stock price. They said behind its negative outlook was its sales arm, which had conducted a massive amount of short selling of Celltrion shares until the nation's financial authorities imposed a temporary ban on the investment scheme, following the spread of COVID-19 in March. Short selling is an investment move betting on a drop in a stock price.

In contrast to JPMorgan, local brokerages have had optimistic outlooks for Celltrion, saying its growth rate shows there is enough room for its stock price to go up further. According to online financial data tracker FnGuide, Korean securities firms set the target price of Celltrion shares at 371,769 won on average.

Over the past few years, Celltrion has suffered from negative reports issued by foreign investment banks, including Goldman Sachs, Deutsche Bank and Morgan Stanley.

Their reports have been considered to be aimed at short selling of the Korean company shares, although they have emphasized that their "Chinese Wall" strictly bars their research and sales arms from exchanging information with each other.

According to industry officials, JPMorgan accounted for 8.2 percent of short selling of Celltrion shares during the first three months of this year.

A high-ranking executive at a local securities firm wishing to remain anonymous raised doubts whether the Chinese Wall in investment banking are really intact, saying foreign firms here are not under as strict supervision by the financial authorities as domestic firms are.

Excerpts articles from The Korea Times
LIST  MODIFY  DELETE  WRITE  REPLY 





전체글 목록 2020. 11. 30.  전체글: 791  방문수: 2617572
 공지  정규직,계약직,프리랜서직 모집 
791   Bank of Korea keeps key rate at record low
790   Boryung's cancer drug line gets GMP certification
789   Exports rise 11.1% in first 20 days of November
788   Crude steel production plummeted in 2020, but demand is rising
787   Korea Development Bank to inject W800 bil. for Korean Air's takeover of Asiana
786   Startups to compete with promising business ideas at Come Up 2020
785   Posco Energy begins operation of LNG terminal
784   Biden targets virus as transition begins
783   Korean won hits 21-month high after Biden win
782   Alibaba posts solid revenue ahead of shopping festival
781   Korea needs to walk tightrope between US and China
780   Gov't, DP compromised on taxing matters
779   Gaming out Lee Kun-hee's estate suggests a few options
778   Korean banks set for fiercer rivalry in Southeast Asia
777   Singapore, UAE top food, water safety list: poll
776   Samsung's Lee Kun-hee passes away at 78
775   Dramatic turnaround for LG Display
774   SK E&C, Veea team up for safety management system
773   SK hynix to acquire Intel’s NAND business for $9 billion
772   Oil Extends Drop With OPEC+ Warning of Precarious Market Outlook
771   YouTube Cracks Down on QAnon Conspiracy Theory, Citing Offline Violence
770   New Hyundai Motor chief set to tackle key tasks 
769   Global watchdog proposes tax overhaul for Big Tech
768   DSME signs 2 trillion won deal for six LNG carriers
767   New innovation or monopolistic abuse?
766   A BTS remix tops charts around world 
765    scientists win Nobel physics prize for black hole finds 
764   Experts question efficacy of gov't measures to bolster fiscal soundness 
763   KakaoPay set to ride on 'IPO craze' in Korea 
762   Virus's unseen hot zone: The American farm 
RELOAD VIEW DEL WRITE
1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 27